# A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Study · id `cardio:ct-nct03689374` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03689374](<https://clinicaltrials.gov/study/NCT03689374>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03689374

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2274 participants.

## Technical summary

Registry record NCT03689374. Randomized; no masking; primary purpose treatment. Start 2018-10-01 (actual); primary completion 2021-02-22 (actual). Results posted on 2022-05-04.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2274 participants (enrolled count; ClinicalTrials.gov record NCT03689374, source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)
- Started: 2018-10-01 (actual) (ClinicalTrials.gov record NCT03689374, source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)
- Primary completion: 2021-02-22 (actual) (ClinicalTrials.gov record NCT03689374, source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)
- Completion: 2021-02-22 (actual) (ClinicalTrials.gov record NCT03689374, source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)
- Results first posted: 2022-05-04 (ClinicalTrials.gov record NCT03689374, source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)
- Countries: Bosnia & Herzegovina; Bulgaria; Croatia; Czechia; Estonia; Germany; Greece; Hungary; India; Latvia; Lithuania; North Macedonia; Poland; Portugal; Romania; Serbia; Slovakia; Slovenia; South Africa; Spain; Türkiye (ClinicalTrials.gov record NCT03689374, source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03689374-2022-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
- Acronym: SUSTAIN 11
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Insulin aspart
- Intervention (Drug): Insulin glargine U100
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial (`cardio:pubmed-35546450`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2f0c226b54f38fb11d32f4d4499b0feb6f0a14d42df88d72e016960a7c6787c9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
